Calendario›REGN›Ubamatamab

Ubamatamab

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Ensayo de REGENERON PHARMACEUTICALS, INC. en Recurrent Ovarian Cancer · Recurrent Fallopian Tube Cancer · Recurrent Primary Peritoneal Cancer · Recurrent Endometrial Cancer · Endometrial Cancer · Low-grade Serous Ovarian Cancer (del registro, en inglés).

Más ensayos de: Cáncer de endometrio.

Fase

Fase 1/2

Estado

Reclutando pacientes

Participantes

890

previstos

Centros

53

Fin del objetivo primario

may 2027

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, no aleatorizado, abierto. Comenzó en may 2018.

Qué mide

Number of participants with Dose-limiting toxicity (DLTs) for ubamatamab monotherapy (From Cycle 1, Day 1 up to 35 days) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThe main purpose of this study is to: * Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus * The study will also look at the levels of ubamatamab and/or cemiplimab in the body and measure how well the body can remove the study drug(s). This is called pharmacokinetics * The study will also look at any signs that ubamatamab alone or with cemiplimab can treat recurrent advanced ovarian cancer or cancer of the uterus * To find out how safe and tolerable pretreatment is in combination with ubamatamab and to see how well it works to prevent or minimize Cytokine Release Syndrome (CRS)

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT03564340), actualizada en sep 2026.